1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • November 2016
  • 433 pages
  • GlobalData
Report ID: 2107728

Summary

Table of Contents

Search Inside

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

Summary

Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions).

The pharmaceutical sales for schizophrenia were approximately US$6.4 Billion throughout the 7MM in 2015. The US contributed to 77.0% of these sales, generating US$4.9 Billion, driven predominantly by sales of atypical antipsychotics. With sales of approximately US$1.0 Billion, Otsuka/Bristol-Myers Squibb’s (BMS’s) Abilify (aripiprazole) accounted for 21.1% of all US sales in 2015.

Global schizophrenia sales are expected to grow to US$7.3 Billion by 2025, at a Compound Annual Growth Rate (CAGR) of 1.4%. The US is set to retain market share over the 10-year forecast period and contribute to 77.2% of sales by 2025, generating approximately US$5.6 Billion.
As per Christos Michaelides, Analyst, “While schizophrenia market growth will primarily be driven by the arrival of late-stage pipeline products, such as Minerva’s MIN-101 and Intra-Cellular Therapies’ ITI-007, both of which are directed towards the treatment of negative symptoms associated with schizophrenia, these symptoms will remain a significant unmet need in the space.

Major drivers of growth of the schizophrenia market during the forecast period include -
- The uptake of novel pipeline products that have been designed to satisfy unmet needs in the disease.
- Development of long-acting injectable (LAI) formulations of atypical antipsychotics in order to improve patient compliance, a notable unmet need.

The report “PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025” provides an overview of schizophrenia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Moreover, this report provides the following analysis -
- Provides Annualized schizophrenia market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Covers market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the schizophrenia therapeutics market.
- Pipeline analysis: focus on nine late-stage pipeline schizophrenia drugs, discussing emerging trends as well as an overview of earlier phase drugs.
- Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Companies mentioned in this report: Alexza Pharmaceuticals, Alkermes, Allergan, Almirall Prodesfarma, Astellas, AstraZeneca, Avanir Pharmaceuticals, Avineuro Pharmaceuticals, Braeburn Pharmaceuticals, Bristol-Myers Squibb, Dainippon Sumitomo/Sunovion, Eli Lilly, Epomedics, Ferrer, Gedeon Richter, HLS Therapeutics, Indivior, Intra-Cellular Therapies, Janssen, Laboratorios Farmaceuticos Rovi, Lundbeck, Meiji Seika, Merck & Co., Minerva Neurosciences, Mitsubishi Tanabe Pharma, Neurocrine Biosciences, Nitto Denko Corporation, Novartis, Otsuka, Pfizer, Sandoz, Sanofi, SyneuRx, Takeda, Teva Pharmaceutical, Titan Pharmaceutical, Vanda Pharmaceuticals, Yoshitomi Yakuhin Corporation.

Highlights

Key Questions Answered

- The schizophrenia market is widely genericized and many of the unexpired patents are due to expire during the forecast period. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
- There are five substantial unmet needs that exist in the schizophrenia market. Will pipeline drugs fulfil any of the unmet needs for schizophrenia? Which unmet needs will continue to provide opportunity for drug developers during the forecast period?
- Out of the nine late-stage pipeline products, six of these are expected to launch during the forecast period to 2025. What impact will these drugs have on the market? How will they affect the treatment algorithm for schizophrenia?

Key Findings

- The main driver of growth in the schizophrenia market will be the uptake of novel pipeline products, such as Minerva Neuroscience’s MIN-101, Intra-Cellular Therapies’ ITI-007, and Alkermes’ ALKS-3831. The pipeline products are forecast to account for 36.2% of the schizophrenia market by 2025 in the 7MM.
- Several pharma companies have focused on developing long acting injectable (LAI) formulations of their oral brands to tailor treatment plans according to patient’s individual needs and improve patient compliance, which is a notable unmet need. Despite the growing popularity of LAIs, this segment is becoming increasingly competitive with three further late-stage pipeline products expected to be launched during the forecast period.
- There are currently no products approved for the treatment of negative symptoms or cognitive impairments associated with schizophrenia, and only one drug approved for treatment-resistant patients. These constitute the major unmet needs in the schizophrenia market.
- The biggest barrier for growth in the schizophrenia market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.

Scope

- Overview of schizophrenia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized schizophrenia market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the schizophrenia therapeutics market.
- Pipeline analysis: focus on nine late-stage pipeline schizophrenia drugs, discussing emerging trends as well as an overview of earlier phase drugs.
- Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global schizophrenia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global schizophrenia therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Parkinson%s disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Sizable pipeline characterized by both high growth and attrition Parkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness ...

Therapeutic Breakthroughs in Alzheimer’s and Parkinson’s Diseases

  • $ 4950
  • Industry report
  • April 2017
  • by Frost & Sullivan

Disease-Modifying Treatments Likely to Transform the Clinical Management of Alzheimer’s and Parkinson’s Diseases The research service primarily encompasses comprehensive analyses of key emerging therapies ...

Central Nervous System Disorder Drugs Markets in China

  • $ 4000
  • Industry report
  • May 2017
  • by Asia Market Information & Development Company

China’s demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.